GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Cyclically Adjusted PB Ratio

Biogen (HAM:IDP) Cyclically Adjusted PB Ratio : 1.40 (As of Jun. 14, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Biogen Cyclically Adjusted PB Ratio?

As of today (2025-06-14), Biogen's current share price is €113.75. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €81.34. Biogen's Cyclically Adjusted PB Ratio for today is 1.40.

The historical rank and industry rank for Biogen's Cyclically Adjusted PB Ratio or its related term are showing as below:

HAM:IDP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.31   Med: 5.39   Max: 13.79
Current: 1.51

During the past years, Biogen's highest Cyclically Adjusted PB Ratio was 13.79. The lowest was 1.31. And the median was 5.39.

HAM:IDP's Cyclically Adjusted PB Ratio is ranked better than
62.01% of 745 companies
in the Drug Manufacturers industry
Industry Median: 1.99 vs HAM:IDP: 1.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's adjusted book value per share data for the three months ended in Mar. 2025 was €107.203. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €81.34 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biogen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted PB Ratio Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.62 3.93 3.96 3.32 1.79

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 2.81 2.30 1.79 1.56

Competitive Comparison of Biogen's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.


;
;

Biogen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biogen's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=113.75/81.34
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Biogen's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=107.203/134.9266*134.9266
=107.203

Current CPI (Mar. 2025) = 134.9266.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201506 47.635 100.684 63.836
201509 42.262 100.392 56.800
201512 39.361 99.792 53.219
201603 42.335 100.470 56.854
201606 46.319 101.688 61.459
201609 49.623 101.861 65.731
201612 53.282 101.863 70.577
201703 50.154 102.862 65.788
201706 48.767 103.349 63.667
201709 51.022 104.136 66.108
201712 50.392 104.011 65.370
201803 54.015 105.290 69.219
201806 52.101 106.317 66.121
201809 58.556 106.507 74.181
201812 58.123 105.998 73.986
201903 62.702 107.251 78.882
201906 62.031 108.070 77.447
201909 69.864 108.329 87.017
201912 68.937 108.420 85.791
202003 67.872 108.902 84.092
202006 63.437 108.767 78.694
202009 59.350 109.815 72.922
202012 57.714 109.897 70.859
202103 59.582 111.754 71.936
202106 59.853 114.631 70.450
202109 60.350 115.734 70.358
202112 65.600 117.630 75.246
202203 69.207 121.301 76.981
202206 77.351 125.017 83.482
202209 89.606 125.227 96.547
202212 87.831 125.222 94.638
202303 88.992 127.348 94.288
202306 92.216 128.729 96.656
202309 93.660 129.860 97.315
202312 93.658 129.419 97.643
202403 96.657 131.776 98.968
202406 102.011 132.554 103.837
202409 101.162 133.029 102.605
202412 109.552 133.157 111.008
202503 107.203 134.927 107.203

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (HAM:IDP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biogen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines